RecruitingNCT07303712
Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90
Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization and Assessment of Treatment Response After Y90 Radioembolization: A Pilot Study
Sponsor
Palo Alto Veterans Institute for Research
Enrollment
12 participants
Start Date
Aug 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Age \> or = 18 years
- HCC confirmed on imaging, BCLC stage 0, A, B, or C
- Transarterial Y90 radioembolization approved by multidisciplinary tumor board -
Exclusion Criteria3
- Not eligible for Y90 procedure
- Prior surgery or ablation on indicated tumors
- Patient unable to complete the follow up visits required for clinical care or research -
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07303712
Related Trials
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
NCT070522531 location
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT0717665051 locations
Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis
NCT074693196 locations
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
NCT05176483122 locations
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT0729107645 locations